Fig. 7
JTE-607 inhibitor exerts anti-tumoral activity in CRPC cells. A Dose–response curve illustrating the growth inhibitory effects of JTE-607 treatment on 22Rv1 cells. Half maximal inhibitory concentration (IC50) for the two cell lines is indicated (mean ± SD, n = 2). B Line graph showing the cell death ratio of LNCaP and 22Rv1 cells treated with 25 µM JTE-607or Dmso at indicated time point (mean ± SD, n = 3, two-way Anova). C Violin plot showing the expression levels of CPSF3 and PCF11 genes in primary prostate adenocarcinoma (PC, n = 429) or normal prostate tissue (n = 43) (TCGA dataset, median value is highlighted, Welch Anova test). D, E Kaplan Meier graphs of the progression free interval (D) and disease free interval (E) survival probability of PC patients in the TCGA database classified according to the expression levels of CSTF3/PCF11 genes. F Representative image of Incucyte® Cytotox green stained 22Rv1 at 48 h of treatment with indicated drugs (JTE-607 6 µM; CPT, cisplatin 1 µM, DCX, docetaxel 3 nM). Violet boundaries highlight cells positive for cytotox green dye. Nuclight Rapid NIR (blue color) stains cells nuclei. G, H Line graphs showing either the cell death ratio of 22Rv1 treated with either 6uM JTE-607 and CPT 1 µM (G, mean ± SD n = 3) or DCX (3 nM) (H, mean ± SD n = 2) alone or in combination with respect to vehicle (Dmso) treated cells (two-way Anova)